A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal
about
Alpha2-adrenergic agonists for the management of opioid withdrawalAlpha2-adrenergic agonists for the management of opioid withdrawalAlpha 2 -adrenergic agonists for the management of opioid withdrawalAlpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients.Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.Pharmacological strategies for detoxification.Opioid dependence treatment: options in pharmacotherapy.Advances in opioid antagonist treatment for opioid addiction.Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteersBuprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Selective review and commentary on emerging pharmacotherapies for opioid addiction.Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients.Comparative Evaluation of Partial α2 -Adrenoceptor Agonist and Pure α2 -Adrenoceptor Antagonist on the Behavioural Symptoms of Withdrawal after Chronic Alcohol Administration in Mice.Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence.Medications for substance use disorders (SUD): emerging approaches.Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.The preclinical discovery of lofexidine for the treatment of opiate addiction.
P2860
Q24185795-C7807994-DBDC-4013-8733-FD1476C2025AQ24197769-D808689C-2F1C-4614-B2A9-4DDDF37E28BEQ24241305-703539A5-9E5F-4776-89D0-320E66849DC1Q33494795-218953AC-51AE-409E-BB88-8FCE28D53473Q33521164-D40DFE83-AECA-48FE-95D9-42868A5C8AFFQ33582092-6770D6C1-EA74-48E9-A9D1-DD3B890296ADQ33868638-FB498F30-4731-4F18-9F9B-A49A3A166C22Q34262649-87906302-EF5A-41F9-81EA-63A7875CCB6DQ34613312-7F3852D5-7758-47F2-89EE-E8D511D0F2ADQ34701089-122F1386-FA07-4B5B-8880-3F776474AEE2Q35090939-2A80C089-0356-4BA7-ACA6-E2209A616E28Q35189633-0CA1CB05-8729-45E8-A374-B4BD9F8C5D6AQ36036175-0529A454-D229-47FA-88F3-CC913ACBB1F7Q36279074-7D2CA8E4-7262-4A4C-93D7-6A00889A6BD4Q36394429-E597FAA4-F56D-45D2-93E7-A0937EF3BD97Q37355286-5744FA1B-F49E-429D-9BF3-63BBFD00B4C5Q45918022-6E76D8FE-4F61-42D7-A042-29AA581CDF70Q47585156-009C6303-46A8-415E-8A63-8A9995B2BEBAQ47711187-D17DB3E6-01FA-4AA1-BB3E-8772CC6C6C61Q47731975-D2933E3A-B965-434F-B247-F6CB6AF965A3Q47815662-344359C5-DDA8-4346-9AE0-A35C408E334EQ52305660-6E21E206-7AC2-4121-8D57-C6428B21A289
P2860
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Phase 3 placebo-controlled, ...... exidine, for opioid withdrawal
@en
A Phase 3 placebo-controlled, ...... xidine, for opioid withdrawal.
@nl
type
label
A Phase 3 placebo-controlled, ...... exidine, for opioid withdrawal
@en
A Phase 3 placebo-controlled, ...... xidine, for opioid withdrawal.
@nl
prefLabel
A Phase 3 placebo-controlled, ...... exidine, for opioid withdrawal
@en
A Phase 3 placebo-controlled, ...... xidine, for opioid withdrawal.
@nl
P2093
P2860
P921
P1476
A Phase 3 placebo-controlled, ...... exidine, for opioid withdrawal
@en
P2093
Ahmed Elkashef
Ann Montgomery
Barbara H Herman
Charles P O'Brien
David K Davies
Evaristo Akerele
Frances McSherry
Herbert Kleber
Ivan Montoya
P2860
P304
P356
10.1016/J.DRUGALCDEP.2008.04.002
P577
2008-05-27T00:00:00Z